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Abstract 
Metabolic disorders affect around thirty-four percent of the population in the United 
States. Among these disorders is lactose intolerance, which results from diminished 
production of the human lactase enzyme. This disorder and others like it are genetically 
determined and cannot be cured. However, the use of transformed bacteria implanted in 
the colon may provide a means by which the faulty pathway can be bypassed. To test 
whether transformed bacteria have the capability to aid in the digestion of normally 
indigestible compounds, a transformed strain of Escherichia coli overexpressing the beta-
galactosidase enzyme encoded by the lacZ gene was colonized in the mouse intestine to 
enhance lactose digestion. The experiment provides the platform for similar research to 
be conducted in the future. 
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The Effect of Transformed Escherichia coli on the Mouse Intestine Microbiome: the 
Microbial Metabolic Enhancement Hypothesis 
Lactose Intolerance as a Disorder 
 Lactose is the primary sugar component of dairy products and is the molecule 
responsible for the characteristic sweetness in these products. Lactose intolerance is a 
condition in which an individual is unable to digest the disaccharide lactose when 
ingested. It results from a body’s inability to produce sufficient amounts of the beta-
galactosidease enzyme lactase, which degrades lactose sugar into glucose and galactose 
monosaccharide units. The production of the enzyme in humans occurs in the cells lining 
the lumen of the small intestine and is secreted in response to the presence of lactose in 
the gastrointestinal tract (1). 
 Mammals characteristically produce milk from mammary glands present in 
female members of mammalian species. Mammalian young feed on the milk produced 
and thus have a higher lactase production rate than that of corresponding adult members 
of a species. Several mammalian adults lose the ability to produce lactase completely and 
thus become lactose intolerant as a result of reaching maturity. Humans are one of the 
few mammalian species that continue to drink milk into adulthood and the only 
mammalian species to drink the milk of other species. Moreover, consumption of food 
products high in lactose has become a large part of cultural diets around the world (1). 
 Many individuals mistakenly call lactose intolerance an allergy to lactose when in 
fact it is not an allergy by the conventional definition. Allergens, or substances that cause 
an allergic reaction, elicit a response from the immune system that often results in the 
release of pro-inflammatory signals and increased immune activity. Lactose intolerance 
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in its common form does not cause these reactions; rather it results in simple stomach 
cramps and possibly diarrhea due to the indigestion of the sugar by the body. The 
symptoms of the disorder make sufferers experience discomfort of varying degrees 
depending on the severity.  
The Mammalian Gut Microbial Community  
 The mammalian colon is home to a number of microorganism species. These 
microorganisms form a microscopic ecosystem in which species compete for energy 
sources and colonization space, much like a macroscopic ecosystem. The 
enterobacterium Escherichia coli (E. coli) is a part of this ecosystem and fills the 
ecological niche of a scavenger in the mammalian gut (2).  
 Gram negative enterobacteria like E. coli make use of broken down disaccharides 
and monosaccharides that result from the catabolic action of obligate anaerobic bacteria, 
such as members of the Bacteroides genera, upon polysaccharide chains extending into 
the mucous layer of the colon. The resulting degradation of polysaccharides results in two 
mucous layers: one with complete polysaccharide chains extending from host intestinal 
epithelial cells and the second comprised of a mixture of mono-, di-, and oligosaccharide 
chains. It is in the partially degraded second layer of carbohydrates above the cellular 
polysaccharide chains that most enterobacteria reside (3). 
 Among various strains of E. coli, and extending to other bacterial populations in 
the gut, there exists a competition for the limited sugar sources available. Moreover, only 
the cell populations that maintain the ability to either make metabolic use of a carbon 
source that other populations cannot use or inherently have better molecular mechanisms 
for enhanced colonizing ability will persist in the intestine and act as a native flora 
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species. The former describes what is known as the nutrient niche hypothesis. Only cells 
that can position themselves in an open space in the ecosystem of the colon will persist 
and proliferate to form a stable population (3). 
 When niches open up in the gut microbiome that pathogenic or even native 
bacteria have the opportunity to cause disease in the host organism. It is when a microbe 
that inhabits a specific niche in the gut is either inadvertently eradicated from the 
ecosystem or is out-competed by a different species or strain that colonization by a 
pathogen can occur. Often the virulence of the given pathogen is at least in part due to its 
attachment to the apical surface of host epithelial cells. Colonization at the apical surface 
in turn results in inflammation and, depending on severity, may lead to serious symptoms 
such as diarrhea and intestinal bleeding (4). 
Lactic Acid Bacteria and the Intestine 
 Lactic acid bacteria are defined as bacterial species that produce lactic acid as a 
byproduct of carbon metabolism. Members of this group are known for their 
consumption of lactose as an energy source. Most belong to the class of bacteria known 
as Firmicutes, which are characterized by gram positive cell wall structure and endospore 
formation.  
 Lactic acid bacteria have been used throughout time as fermenting agents in the 
production of dairy products such as yogurt and kefir and fermented vegetable foods like 
sauerkraut and kimchi. Consumption of fermented foods has been linked to intestinal 
health, as the lactic acid bacteria contained within promote better digestion of certain 
energy sources (5).  
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 A genera of lactic acid bacteria known as Lactobacillus is actually part of the 
normal flora in the human body. In the early stages of life, infants have a higher amount 
of Lactobacillus bacteria residing in the colon than adults. This could be attributed to the 
need of infants to obtain virtually all of their nutrition from the milk of the mother, which 
contains large amounts of lactose sugar. Hence, with a higher percentage of lactic acid 
bacteria in the colon, it may be assumed that there is a higher amount of lactose 
catabolism carried out by such bacteria. The phenomenon may point to the gut 
microbiome playing an important role in lactose degradation in the early stages of life 
and possibly into adulthood as well (6).  
 Physiologically, most people from the country of Indonesia are lactose intolerant; 
the gastrointestinal tracts of these individuals do not produce lactase. However, such 
individuals are able to consume large amounts of dairy products without experiencing the 
symptoms of lactose intolerance (5). The lack of symptoms is counterintuitive until one 
realizes that large amounts of yogurt containing live lactic acid bacteria cultures are also 
consumed with the dairy products. The bacteria, many of which are Lactobacilli, thus 
consume the lactose in the dairy products and prevent the symptoms from occurring. This 
is the concept behind the use of probiotics, most of which contain several species of 
Lactobacillus and Bifidobacterium, another genera of lactic acid bacteria (7).  
 These bacterial species may provide aid to lactose intolerance sufferers in the 
digestion of lactose. However, most, if not all, lactic acid bacteria are poor colonizers of 
the mature adult gastrointestinal tract. Due to the nutrient niche factor, there are no open 
ecological niches for these species to inhabit, thus they are either out-competed and die 
shortly after ingestion or are shed in feces. To provide a permanent solution to lactose 
MICROBIAL METABOLIC ENHANCEMENT 8 
intolerance, a bacterial species that colonizes the adult mammalian gut well must be 
genetically transformed to digest lactose with a fast enough rate to degrade the sugar 
before symptoms can manifest. 
The Microbial Metabolic Enhancement Hypothesis 
 Genetic transformation of microorganisms is not a novel idea. Scientists have 
been using genetically modified microorganisms along with a plethora of other similarly 
modified organisms to express desired traits for decades. For instance, it is now quite 
common for diabetic patients to receive human insulin produced by recombinant E. coli 
cells expressing the human INS gene (8). Recombinant cells like those producing insulin 
are thus used for the production of desired biomolecules for research and/or medical 
applications. 
 Such recombinant cells have only occasionally been cultured in vivo for the 
purpose of treating disease or deficiency. They are typically cultured in vitro and their 
subsequent products harvested from culture media. However, the transformation of 
microorganisms native to the human microbiome could result in a potential source of 
novel metabolic activity occurring within the human host for the purpose of filling a void 
left by a metabolic deficiency in the host. Strategic genetic transformation of native 
microbes in the human body could result in novel metabolic pathways in the microbes 
themselves. These novel pathways could then be used to degrade or generate 
biomolecules in a patient that lacks the metabolic capability to do so on their own. 
Colonization of the microbe at a target site could fulfill the metabolic need if 
corresponding residential strains are either out-competed or eliminated with antibiotics. 
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This proposed novel use of transformed microbes to fill a metabolic deficit will be 
henceforth referred to as the microbial metabolic enhancement hypothesis (MME). 
Colonization of Transformed E. coli in the Streptomycin Treated Gut 
 This study aims to determine if a strain of Escherichia coli transformed with an 
enhanced ability to catabolize lactose can colonize in a streptomycin-treated mouse 
intestine and possibly ease the symptoms of lactose intolerance in the murine host. Mice, 
like most small mammals, are completely lactose intolerant into adulthood, despite the 
commonly held belief that mice enjoy cheese regularly. As a result, they serve as an 
excellent model for testing the efficacy of a lactose intolerance treatment.  
 Streptomycin is an antibiotic that specifically targets the gram negative 
Enterobacteria, including E. coli. The streptomycin-treated gut is therefore devoid of 
most Enterobacteria (9). The only Enterobacteria that survive are those that have 
spontaneous antibiotic resistance to streptomycin. Several strains of E. coli resistant to 
the antibiotic have been isolated in research settings. One sub-strain of the E. coli K12 
strain MG1655 has been isolated for streptomycin resistance and is thus able to be used 
in the streptomycin-treated gut. The nutrient niche factor would not impede the 
colonization of the strain, as the niches normally inhabited by native Enterobacteria 
would be left open subsequent to streptomycin treatment. The streptomycin-resistant 
mutant (MG1655 Strr) was thus determined to be the perfect strain to use for 
transformation (10).  
 Initially, a wild type strain of MG1655 (MG1655 Strr Nalr) was co-colonized with 
a knockout mutant strain lacking the lacZ gene (MG1655 ΔlacZ) - the gene encoding the 
enzyme beta-galactosidease - in a streptomycin treated mouse (2, 11). The mouse host 
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was given drinking water with fifteen percent lactose to simulate a lactose rich diet. A 
second co-colonization was done using a derived strain of MG1655 that has been 
complemented for the lacZ gene. This restored strain was made using a plasmid vector 
under lac operon control from an E. coli strain from the ASKA collection of 
overexpressing E. coli mutants (12). The first co-colonization serves to determine the 
importance of lactose to E. coli MG1655 in the colon in regards to competitive ability. 
The second allows for the establishment of a mutant strain expressing lactase activity that 
can be controlled and regulated in the mouse intestine and allows for the mutant strain’s 
competition with the wild type strain to be studied. 
 Literature Review: Potential Application 
Background on Metabolic Disorders 
 Metabolic disorders are classified as illnesses that are genetically determined and 
prevent proper catabolism or anabolism of a given molecule or class of molecules. 
Sufferers of these disorders are therefore unable to process the substrate correctly, 
typically resulting in a detrimental buildup of the molecule in the body. The buildup then 
interferes with other biological functions and results in the symptoms of the disease. 
Current treatments for such disorders are quite limited in scope, and there is no cure for 
these illnesses to date. Often times, the subject is required to modify his or her own 
dietary intake of food to accommodate the body’s inability to metabolize these harmful 
substances. Such modifications can make the intake of vital nutrients difficult if their 
sources coincide with the sources of the metabolically toxic molecules.  
 Some potential treatments, such as enzyme, drug, and gene therapy, have been 
explored at various lengths. However, each method has its own disadvantages. Enzyme 
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therapy allows for the direct injection of functional catabolic proteins into the blood or to 
the site of metabolic buildup. The enzymes fill the void created by the absence of the 
same or similar enzymes that would be present in a phenotypically normal person. Drug 
therapy involves using molecules that modulate the way the harmful molecule acts in the 
body. Such drugs can block cell receptors, lower blood levels, or even alter the chemical 
composition of the harmful substance to make it more tolerable by the body. While both 
of these treatments have had success in treating patients, the patient is required to receive 
the treatment continuously for life. Both treatments are therefore expensive endeavors 
that many are certainly unable to afford.  
 Gene therapy provides a more permanent solution to the problem, in that it 
directly attempts to repair an individual’s altered gene(s) to allow them to produce the 
necessary metabolic pathway constituents on their own. Gene therapy involves the 
removal of a subject’s body cells to be subsequently cultured and genetically modified by 
a number of different means before being returned to the body. While gene therapy 
would provide a more permanent solution, several risk factors, including potential 
autoimmune response against the cells and potential viral infection of the genome, make 
this treatment highly controversial and hazardous.  
 It can therefore be concluded that for a metabolic disorder treatment to have the 
best effect, it needs to be semi-permanent, meaning only rarely requiring repetitious 
instances, physiologically safe, and have the potential to be terminated if the body reacts 
adversely to it. Several metabolic disorders may be curable when the concept of MME is 
applied as proposed in this paper. Microbes can be transformed to produce any number of 
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enzymes and factors which could potentially fill the metabolic void left by genetic 
mutation of the host.  
Urea Cycle Disorders and Ammonia Oxidation 
Ammonia is a byproduct of catabolism of nitrogenous organic molecules in 
several eukaryotic life forms. In mammalian metabolism, ammonia waste is produced 
from the deamination of amino acids. Deamination in the liver results in the production 
of ammonia and organic acid. The organic acid is used in intracellular mitochondria as an 
energy source for aerobic respiration, whereas the ammonia cannot be used for energy 
and must be converted to urea, a less toxic nitrogenous waste, and excreted from the 
body. Many enzymes are involved in this pathway, and malfunction in some of them can 
be disastrous (13).  
The urea cycle is a highly complex metabolic pathway in the mammalian body 
involving enzymes present in the hepatic cell cytoplasm and within the hepatic cell 
mitochondria. After amino acid deamination, ammonia, existing as ammonium in the 
blood due to pH, travels to the liver where the hepatic cell mitochondria combine it with 
bicarbonate using the CPSI enzyme to produce carbamoyl phosphate. A series of 
enzymes then convert the substrate into many subsequent metabolites before finally 
converting it into either fumarate or urea. Urea is subsequently transported by the blood 
to the kidney, where it is filtered into urine and eventually excreted (14).  
Deleterious mutations are the destructive factor in urea cycle diseases and are 
present in the individual at birth. Due to early exposure to compounds that could not be 
metabolized in such individuals, several harmful secondary symptoms can result from 
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urea cycle-related mutations. Among these are mental retardation due to ammonia build 
up in the cerebrum (15). 
Ammonia oxidation, also called nitrification, was once thought to be a very well-
known process in the  nitrogen cycle. The process involves taking the toxic, nitrogenous 
waste ammonia and converting it to a less toxic form, nitrite, which is subsequently 
converted to nitrate. This process is carried out by various bacteria species in soil and 
marine environments and allows the nitrogen in ammonia to be reused in biological 
processes in higher organisms or to be rereleased into the atmosphere as nitrogen gas 
(16).  
Another group of organisms has been shown to have an equally important role in 
ammonia oxidation in low oxygen conditions. These microorganisms belong to the 
domain Archaea, a group of prokaryotes completely separate from Bacteria. Archaea 
superficially resemble bacteria, but their genetic code and metabolic pathways actually 
better resemble members of Eukarya. Ammonia oxidizing archaea (AOA) use a yet to be 
understood metabolic pathway to aerobically convert ammonia to nitrate, similar to the 
bacteria mentioned previously. The key difference between AOA and ammonia oxidizing 
bacteria (AOB) is that AOA are largely more efficient in their metabolism of ammonia, 
being able to thrive even at nanomolar concentrations of ammonia. This results from the 
high affinity these organisms have for ammonia. AOA have been identified in both soil 
environments and marine environments, competing with both anammox and classical 
AOB (16, 17). 
Transformation of E. coli with ammonia oxidation genes could provide a means 
by which ammonia in the body of a urea cycle disorder patient could be detoxified in an 
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effective manner. The amoA gene from AOA species could be a possible candidate by 
which an ammonia oxidative E. coli strain could be generated. An interesting experiment 
would be to construct two E. coli mutants, one with AOB ammonia oxidation genes and 
one with AOA ammonia oxidation genes. When colonized within a mouse model with 
high levels of ammonia, the strain that colonizes best would be the strain to use for urea 
cycle disorder treatment. The competing strains would also need to be analyzed for total 
ammonia oxidative activity. 
A major weakness of this approach is the lack of understanding of what effect 
oxidized ammonia products such as nitrate and nitrite could have on the total health of 
the gastrointestinal tract. As ammonia oxidation has never been carried out in the 
intestine, a thorough investigation of the long term affects the reaction could have on the 
host must be undertaken before even considered as a treatment option. While nitrate and 
nitrite are less toxic than ammonia, they may have long-term health risks if produced in 
large amounts in the colon. 
Additionally, it must be determined if the location of ammonia oxidation in the 
intestine would even provide sufficient detoxification of ammonia to prevent urea cycle 
disorder symptoms from manifesting. The intestine may not be the optimal location for 
ammonia detoxification to occur. The transformed strains might not even be provided 
sufficient access to blood ammonia to be able to detoxify it from the colon. If a 
significant amount of ammonia is left in the blood even with ammonia oxidative E. coli 
in the colon, a different site of colonization should be considered.   
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Diabetes and Insulin Production 
Diabetes is a disorder in which an individual’s body is unable to regulate the 
glucose content of the blood due to a deficiency of a necessary signaling factor. Often, it 
is a mutation in the human INS gene that results in the disorder. The INS gene encodes 
for the signal peptide insulin. Insulin regulates blood glucose levels by causing body cells 
to internalize more glucose, thus removing the molecule from the blood. When a 
mutation exists in the INS gene, the body cannot produce its own fully functional insulin. 
When the cause of the disease is a deleterious mutation of the INS gene, the disorder is 
known as type II diabetes. Patients with this disease are forced to receive insulin usually 
in the form of an injection directly to the bloodstream in order to maintain blood glucose 
levels. Currently, insulin used by patients is produced by mutant E. coli strains 
transformed with the human INS gene (18). 
Before the use of E. coli, patients had to receive insulin harvested from horses or 
other livestock. Using insulin produced by different animals was generally considered 
safe at the time. However, due to the slight variations in protein structure, patients would 
often have allergic reactions to the treatment, or the treatment would not be sufficiently 
effective to control blood sugar levels (8). Insulin production by E. coli, and afterward 
Sacromyces cerviciae, resulted in the availability of virtually endless supplies of the 
protein in human form. The body of patients therefore do not react adversely to the 
treatment.  
 While insulin has been produced by E. coli for years, the insulin producing 
bacteria have only been grown in in vitro conditions. The insulin is harvested from the 
cells in large bioreactors. Recombinant cells are grown and subsequently broken open to 
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release the human protein. Refinement of the cell lysate allows for the isolation of human 
insulin for packaging and shipping. The process kills all the cells and requires re-
inoculation of the bioreactor with a fresh E. coli inoculum. Large sums of money are 
spent on media in which to grow the cells in and requires a great deal of coordination of 
advanced techniques to isolate the insulin itself from the cells (19).  
 Due to the native presence of E. coli in the intestine, it is feasible that 
recombinant cells expressing the human INS gene could colonize in the colon and 
produce insulin indefinitely within the host organism. The result would be a pool of 
insulin ever present in the colon, minimizing the need for further treatment. Only 
occasional emergency re-colonization of the recombinant strain would be required should 
the gut environment become hostile to the recombinant strain. 
 Several challenges would have to be overcome for such a treatment to be 
successful. First, no insulin producing E. coli mutant has thus far been designed to secrete 
the insulin itself. For a recombinant population of E. coli to thrive in the gut, it is 
imperative that they continue to live and propagate over many generations. Current 
methods of insulin harvest from E. coli involve the breaking open of the cells, which 
obviously kills them in the process. A mechanism of secretion must be established for a 
colonizing E. coli INS strain to be successful in treating diabetes. Secretion of insulin 
may be attainable via translocon insertion into the E. coli genome. The solution involves 
the insertion of a gene for a eukaryotic translocon protein that would allow for the active 
transport of the insulin peptide out of the bacterial cell. 
 The second foreseeable challenge would be the control of insulin production in 
the recombinant population. The production of the peptide would need to be only allowed 
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after high glucose intake. Too much insulin would not allow any glucose to be in the 
blood, which would be disastrous for the entire body. Putting the INS gene under operon 
regulation may present a possible solution. If the INS gene were incorporated into a lac 
operon, the gene would only be transcribed in the presence of lactose or a lactose analog. 
Having to take an enteric coated lactose pill to receive diabetes treatment would be a 
great deal less expensive than relying on insulin injections for life.   
Enhanced Cellulose Catabolism 
 Cellulose is the most abundant carbohydrate on the planet, being produced in 
some capacity by all plants and even algae. The carbohydrate serves as a structural 
component in the cell wall of plant cells that give them their characteristic rigidity. 
Synthesis of cellulose is carried out by a series of cellulose synthase enzyme complexes 
near the plasma membrane of the plant cell. The complexes bind individual glucose ring 
molecules together via condensation reaction at carbons one and four. The particular type 
of bond formed between two glucose rings in cellulose chains is known as a beta 
glycosidic bond. Few organisms possess the proper enzymatic equipment to break this 
bond, thus releasing glucose for metabolic energy acquisition (20). 
 A cellulase is an enzyme involved with the degradation of cellulose. The term 
cellulase is somewhat generic, as there is not one specific enzyme that carries out the 
function. Cellulases are thus spread across a wide variety of organisms, both prokaryotic 
and eukaryotic, and degrade the polysaccharide chain in various ways. In general, 
cellulase enzymes fall into three main categories: endoglucanases, exoglucanases, and 
beta-glucosidases. Endoglucanases function by separating individual cellulose chains 
from the stacked configuration they naturally take. Exoglucanases cleave disaccharide 
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cellobiose units from the ends of the cellulose chains. Beta-glucosidease break the 
cellobiose units into individual glucose monomers that can be used for respiration (21). 
E. coli strains have been transformed to degrade vegetable matter by action of 
cellulase enzymes in the biofuel industry. Genes from various cellulolytic bacterial 
species have been used to produce mutant cellulolytic E. coli. A study by Rodrigues et al. 
made use of an endoglucanase gene from Firmicute Bacillus pumilus and a beta-
glucosidease gene from the thermophilic species Fervidobacterium to produce an E. coli 
mutant producing both of these enzymes for enhanced bioethanol production (22). The 
result was a strain that could grow on cellulose media twice as fast as strains possessing 
only one or the other cellulase genes. 
Mammalian ruminants have a plethora of cellulolytic bacterial species that 
colonize their specialized intestinal tracts, typically from the genus Clostridium (23). As 
with Lactobacillus, however, it would be impossible to get these species to colonize the 
gut when ecological niches have already been established. Therefore, using a cellulolytic 
E. coli strain similar to the one mentioned earlier would be necessary to have cellulolytic 
activity in the intestine. The principal potential benefit that such a colonization could 
bring about is the ability for the body to obtain fuel from sources normally thought of as 
indigestible. Humans typically eat a wide variety of plant-based foods, but most of the 
energy in the form of cellulose is never accessed due to the limits of the native intestinal 
microbiota. Colonization by cellulolytic strains could allow malnourished people in 
impoverished situations to access energy from virtually any form of plant matter. 
One foreseeable issue is the need for the secretion of cellulase enzymes to 
generate glucose outside of the bacterial cell wall. Only glucose formed in the lumen of 
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the colon could have the potential to be absorbed by the bloodstream and thus be used by 
the body. Fortunately, many strains already produced for the biofuel industry that secrete 
cellulase enzymes have been created. Thus, the genetic material encoding for cellulolytic 
ability from these strains would be optimal for generating an E. coli strain to be used 
practically.  
Applications Outside the Intestine 
 While the gastrointestinal tract is a hub of sorts for metabolic activity of native 
microbiota, there are several other sites in and on the body where microorganisms abound. 
Other microbes could thus be exploited for metabolic enhancement as with E. coli. A very 
wide range of disorders could be treated in this manner. 
 For instance, the human skin is covered with several species of Staphylococcus, 
characterized by coccus morphology and gram positive staining. Staphylococcus bacteria 
typically exist in a commensal relationship with the host, posing no immediate threat. 
However, if left unattended, an open wound in the skin could serve as the site of a 
nosocomial infection by at least some Staphylococcus species. Therefore, Staphylococcus 
bacteria have a reputation for being opportunistic pathogens (24, 25).  
 Despite the pathogenic potential, Staphylococcus species have been studied for 
their potential benefit to the host by preventing harmful, purely pathogenic microbes 
from colonizing on the surface of the skin. Moreover, it can be said that the concept of 
the nutrient niche hypothesis may apply even on the skin. The protective role of 
Staphylococcus bacteria could be amplified via genetic transformation.  
 To establish a fortified skin microbiome, the pathogenicity of the Staphylococcus 
strain to be utilized must be removed completely. While several virulence factors exist, 
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removing genetic information for one or several master regulator transcription factors 
promoting virulent expression may be successful in preventing the transcription of 
virulence factor genes (24, 25). The non-pathogenic strain must then be transformed with 
one or several forms of antibiotic resistance, preventing its removal from the skin with 
antibiotic treatment. Subsequent antibiotic treatment would then kill transient pathogenic 
bacteria while allowing the resistant strain to flourish. When confronted with a skin 
environment where there is no available niche due to the overcolonization of the resistant 
strain, pathogens would be unable to compete and would thus die out. This method could 
provide much-needed extra defense for immunocompromised patients at highest risk for 
nosocomial infection.  
Materials and Methods 
Bacterial Strains 
 The E. coli strains used in this study (Table 1) were all derived from E. coli K12, 
a strain originally isolated from the colon of a diphtheria patient in Palo Alto, CA, in 
1922. The MG1655 strain was derived from a K12 strain cured of a bacteriophage 
infection (9). MG1655 has since been widely used in laboratory applications. The 
MG1655 Strr strain is a mutant spontaneously resistant to streptomycin (11).  
 MG1655 ΔlacZ is a knockout mutant for the lacZ gene (2). The gene encodes the 
enzyme beta-galactosidease and is normally under the regulation of an operon upstream 
of the promoter. The knockout mutant produces no beta-galactosidease as a direct result 
of the genotype.  
 MG1655 lacZ* is a clone of the MG1655 ΔlacZ strain with the addition of a 
plasmid vector containing a kanamycin resistance cassette and a functional lacZ gene 
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under lac operon regulation. The strain thus has restored production of beta-galactosidase 
when under lactose induction. The vector was constructed from the amplified DNA of an 
E. coli strain from the ASKA collection (12).  
 
Table 1. Bacterial Strains Used and Supporting Information 
E. coli Strain  Resistance Phenotype Reference 
MG1655 Strr  Streptomycin, Nalidixic 
Acid 
Wild type MG1655 
with spontaneous 
antibiotic resistance 
(11) 
MG1655 ΔlacZ Streptomycin, 
Chloramphenicol 
Deletion mutation of 
lacZ, resulting in β-
galactosidease 
deficiency 
(2) 
MG1655 lacZ* Streptomycin, 
Kanamycin 
MG1655 ΔlacZ with 
ASKA lac operon 
controlled lacZ vector 
(12), this study 
 
MG1655 lacZ* Construction 
 Construction of the lacZ recovery strain MG1655 lacZ* was carried out via 
electroporation of the MG1655 ΔlacZ mutant with isolated and amplified plasmid vector 
pCA24N from an ASKA collection strain overexpressing lacZ. Polymerase chain 
reaction was performed to amplify the pCA24N vector. The reaction was gel purified 
following separation on a 0.7% agarose gel. The MinElute Gel Extraction kit (#28604) 
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was used to isolate the amplified plasmid. Electroporation of the MG1655 ΔlacZ strain 
with the isolated plasmid was performed at 24.5 kV. The strain was subsequently 
incubated in SOC media for one hour at 37oC prior to plating onto agar medium with 
kanamycin. Single colony frozen stocks of the generated MG1655 lacZ* mutant were 
subsequently made (12). 
Biolog Metabolic Analysis of Strains 
 The Biolog GEN III MicroPlate test panel was used to investigate the metabolic 
capabilities of the strains used before colonization in streptomycin-treated mice. Each 
strain was inoculated onto agar media plates with proper antibiotics from frozen stock. 
The plates were allowed to incubate for 18 hours at 37oC. The cultures were then 
removed and inoculated into aliquots of IF-A solution to an optical density (OD) of 0.05. 
The cell suspension was then loaded into each well of the Biolog microplate (100µL per 
well). The plates were then allowed to incubate for 18 hours before data analysis was 
performed (26). 
Mouse Co-colonization with MG1655 WT and Mutant Strains 
 Initial streptomycin sulfate treatment (5 g/L in drinking water) was performed on 
weaned BALB/c mice (Charles River, Kingston, NY) 48 hours before strain inoculation 
to clear their colons of resident Enterobacteria. Food and streptomycin water were 
removed 24 hours before inoculation to encourage mouse ingestion of strain inoculum. 
Single-colony inoculations of broth cultures for competing strains were made after 
removal of food and water. After an 18-hour incubation, 5 μL were taken from each 
culture and added to 990 μL of 20% sucrose solution. This was repeated for each mouse. 
The bacterial suspensions were then serially diluted to obtain viable count data. The 
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sucrose suspension was fed to each mouse and food and streptomycin water were 
returned. The mice were given 15% lactose in solution with the drinking water to 
simulate a high lactose diet. Fecal collections were performed 5 hours after inoculation. 
One gram of feces was collected per mouse and diluted in 10 mL of tryptone each. Ten-
fold serial dilutions of the fecal suspensions were performed. Dilutions were then plated 
onto MacConkey agar media containing streptomycin and either nalidixic acid, 
chloramphenicol, or kanamycin, depending on the strain to be isolated. CFU counts were 
then enumerated for each dilution plate. Subsequent collections occurred every day for 15 
days total (2).  
Results 
Metabolic Analysis of MG1655 ΔlacZ Confirms Strain Metabolic Deficiency 
 The Biolog test panel measured the ability of E. coli MG1655 ΔlacZ to grow on 
95 different carbon sources (Figure 1). Through this assay, it was confirmed that 
MG1655 ΔlacZ does not grow on lactose. It is expected that the wild type strain will 
retain the ability to grow on lactose. Further metabolic analysis will be performed on 
restored the MG1655 lacZ* strain to ensure the strain is capable of growing on lactose. 
Spectrophotometric analysis of the test panel media will provide an empirical measure of 
the carbon catabolic activity of each strain. Special attention will be paid to lactose.  
 It is worth noting that the MG1655 ΔlacZ Biolog plate revealed that the strain is 
capable of growing on cellobiose, the disaccharide product  of cellulose carbohydrate 
chain breakdown. It is also worth noting that the strain was able to grow on several 
antibiotic containing wells, including those with nalidixic acid and vancomycin. This is 
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B) 
A) 
surprising, as resistance to these antibiotics has not been previously described for this 
strain.  
 
                          
 
 
 
 
 
Figure 1. Biolog GEN III MicroPlate test panel of MG1655 
ΔlacZ. When the assay plate (A) is compared with the test panel 
grid (B), the catabolic activity of the strain can be determined. 
Assay plate and test grid provided by Biolog, Inc. 
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Metabolic Analysis of MG1655 Strr Confirms Lactose Catabolism 
 The Biolog test panel was also used to measure the catabolic activity of the 
MG1655 Strr strain (Figure 2). The Biolog assay confirmed that the strain does indeed 
catabolize lactose, affirming its potential as a competitor against the mutant ΔlacZ strain 
in a streptomycin-treated mouse colonization.  
 The strain also grew in the presence of naldixic acid and vancomycin, similar to 
the ΔlacZ strain. Resistance to these antibiotics is not imbued to these bacteria via gene 
vector, suggesting the strains obtained resistance to the antibiotics through a different 
means. 
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Due to outside circumstances, the mouse colonization portion of the experiment 
was unable to be performed before time of this publication.  
 
Figure 2. Biolog GEN III MicroPlate test panel of MG1655 Strr. 
When the assay plate (A) is compared with the test panel grid (B), 
the catabolic activity of the strain can be determined. Assay plate 
and test grid provided by Biolog, Inc. 
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Discussion 
 The lack of lactose catabolism in the MG1655 ΔlacZ strain allows it to act as a 
negative control in the experiment. It can be expected in the lactose-fed mouse 
colonization that the colony forming unit (CFU) count of each strain will be indicative of 
which strain is the better colonizer in a high-lactose environment. Whether the knockout 
strain is outcompeted or not by the wild type will provide an indication of the importance 
of lactose to colon colonizing microbiota.  
 The mouse colonization with MG1655 Strr and MG1655 ΔlacZ is expected to 
reveal aspects of the importance of lactose catabolism in the mouse intestine. With the 
high influx of lactose sugar into the colon due to the treatment in the study, it can be 
expected that this carbon source will play a role in strain selection, resulting in the out-
competition of one strain over the other. It is likely that the MG1655 Strr will outcompete 
the MG1655 ΔlacZ due to the ability the former strain has to utilize lactose sugar as a 
carbon source. The nutrient niche hypothesis states that the more nutrient sources a 
bacterium has access to in the colon, the better it competes in the gut ecosystem (2). The 
fact that the mutant strain cannot utilize lactose, which will be prevalent in the colon with 
the treatment, points to the likelihood that it will be outcompeted. However, if the strain 
is not outcompeted, then it will be shown that lactose is not an important sugar to the 
enterobacterial community in regard to niche competition. 
 The cellobiose catabolism could be important in regard to the potential 
transformation of E. coli to cellulolytic bacterium, a subject discussed in length earlier in 
this paper. If the mutant is capable of digesting cellobiose, then it is possible that the wild 
type strain is capable of doing the same. If the wild type is capable of digesting 
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cellobiose, then transforming the strain to digest cellulose polysaccharide fully would be 
an easier feat to accomplish. A transformation with a gene to break down cellulose into 
disaccharide cellobiose units would be the only necessary procedure to make E. coli 
completely cellulolytic.  
Conclusions 
 While still very much only an idea, there are fragments of the MME hypothesis 
scattered throughout current microbe-host interaction studies. Microorganisms and host 
animals may rely on one another more than previously thought, especially in the sense of 
the latter on the former. In the modern era of antibiotic treatments and sanitization, 
humans have effectively lowered the risk of infection, but they have simultaneously 
downplayed the importance of native microbiota to health. By strategically enhancing the 
microbes already present in and on the human body, sufferers of disorders and diseases 
thought previously to be incurable may have a chance to live a much more normal life. 
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